FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation
The addition of concurrent chemotherapy to definitive radiation has improved the 5-year
survival of women with locally advanced cervical cancer to 58%. To determine if plasma HPV
DNA predates clinical recurrence and/or improves the accuracy of metabolic response on
FDG-PET at 3 months post completion of radical chemo-radiation in patients with locally
advanced cervical cancer. Post therapy FDG-PET can help predict progression free survival
and overall survival. In addition plasma HPV can be used to monitor response and detect
early recurrence. Prospective study will recruit 20 patients with locally advanced cervical
cancer to determine if plasma HPV DNA predates clinical recurrence and/or improves the
accuracy response on post-therapy FDG-PET scan at 3 months.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society